Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.
| Jazyk: | angličtina |
|---|---|
| Zdroj: | Blood advances [Blood Adv] 2022 Nov 22; Vol. 6 (22), pp. 5886. |
| DOI: | 10.1182/bloodadvances.2022009077 |
| Databáze: | MEDLINE |
| Externí odkaz: |
|